• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Narasimhan
Biotech

Novartis CEO says shareholders ‘happy overall’ despite setbacks

CEO Vas Narasimhan told Fierce he believes most shareholders remain onside, while calling for adjustments to the U.S. Treasury's China plans.
James Waldron , Angus Liu Nov 19, 2026 4:16am
Fierce London event panel

Big Pharmas tell Fierce's London event about their ideal biotech

Nov 18, 2026 5:18am
dollar sign pipeline

Evaxion halts infectious disease work in R&D refocus on oncology

Nov 19, 2026 10:02am
Layoffs

nChroma halves headcount, halts trial of potential HBV ‘cure’

Nov 19, 2026 9:08am
Merck

Isomorphic adds Merck to drug discovery roster after $5B raise

Nov 19, 2026 8:47am
Teva

Teva loses R&D head amid push to grow innovative medicines unit

Nov 19, 2026 8:28am
More News

Fierce Biotech Fundraising Tracker '26: VitriVax, Ansa & more

Nov 19, 2026 5:00am

AbbVie busts a move with Disco in $2.5B bispecific dance

Nov 19, 2026 4:30am

Biogen’s tau drug drives bigger benefits in Alzheimer’s update

Nov 18, 2026 9:26am

Clene uses Veristat’s biostatistics platform for FDA submission

Nov 18, 2026 9:00am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings